Cell Line Development Services Market Estimated To Experience A Hike In Growth With UЅD $2,444.2 Мn By 2030
Cell line development requires the discovery of a single cell-derived clones that produce high and consistent levels of the target therapeutic protein. Cell lines have revolutionized scientific research and are presently being used in vaccine production, testing drug metabolism and cytotoxicity, the generation of artificial tissue, the study of gene function, antibody production, etc. Cell line development services enable researchers to benefit from the advantages of comprehensive workflows can begin from the desired gene sequence to the stable cell line, including verification procedures.
The Global Cell Line Development Services Market was valued at UЅD $789.3 Мn in 2020, and is projected to achieve a valuation of UЅD $2,444.2 Мn by 2030, at a САGR of 14.2%. The 5-year (2021–2026) cumulative revenue of this market is projected to be over USD $1,646.9 Mn, and is estimated to increase significantly over the latter part of the forecast period.
The increasing incidence of various disorders such as psoriasis, diabetes, anaemia, Crohn’s disease, rheumatoid arthritis, various cancers, age-related macular degeneration, etc., across the world, as well as the increasing prevalence of immunology disorders among individuals of varying ages is a major factor that is anticipated to continue to fuel the projected revenue growth of the global cell line development services market over the next decade. Moreover, the increasing prominence of biosimilars due to the lower costs required needed as well as shorter durations to develop, is another major factor that is slated to compliment opportunities for additional market growth in the coming years. Furthermore, increasing investments being channelled by key industry players towards improving the development, screening, and manufacturing technologies, as well as the incorporation of automation and robotics in cell line processes are also factor that are slated to influence this global market. In addition, as a result of the COVID-19 outbreak, numerous researchers are now seeking to extensively use these services to develop effective forms of treatment.
Nonetheless, the various complexities that are involved in the development of cell lines and the high-risk potential of tainted samples are some of the factor that may restrain the revenue growth of the global cell line development services market in the foreseeable future.
Regardless, the ever-surging demand for highly productive and stable lines for both market players and potential non-industry players is another factor that is anticipated to continue to influence the revenue growth of the global cell line development services market in the foreseeable future.
Segmentation of the global cell line development services market is as follows:
In terms of product type, the reagents & media segment accounted for the maximum number of revenue shares of the global cell line development services market in 2020, and is expected to continue doing so over the forecast period. The equipment segment is also anticipated to index a high CAGR over the next 10 years.
With regards to type, the recombinant cell lines segment accounted for the highest number of revenue shares of the global cell line development services market in 2020, and is anticipated to register the highest CAGR over the next decade. The hybridomas segment is also expected to register considerable revenue growth in the years to come.
On the basis of application, the drug discovery segment accounted for the maximum number of revenue shares in 2020, and this segment is anticipated to index the highest CAGR in the coming years. The bioproduction segment is slated to account the second-most number of revenue shares by the end of the forecast period.
With respect to source, the mammalian cell line segment accounted for the maximum number of revenue shares in 2020, and this segment is expected to continue to do so in the foreseeable future.
Key Players: General Electric (GE Healthcare), Thermo Fisher Scientific Inc., FUJIFILM Holdings Corp. (FUJIFILM Diosynth Biotechnologies U.S.A., Inc.), Merck KGaA (Sigma-Aldrich Corporation), Lonza Group AG, JSR Corporation (Selexis SA), Sartorius AG, WuXi AppTec Co. Ltd. (WuXi Biologics), MabPlex USA Inc., Solentim Ltd.
Regional Segmentation and Analysis:
North America accounted for the maximum number of revenue shares of the global cell line development services market in 2020, and are indicative of remaining this industry’s front-runner. The markets in Europe and the Asia Pacific regions accounted for the second-, and the third-most number of revenue shares in 2020, and are anticipated to continue doing so over the next 10 years.
Browse Detailed Insights Of Cell Line Development Services Market Here: https://marketresearch.biz/report/cell-line-development-services-market/